CD5 and inflammatory bowel disease: Our results demonstrate that chronic intestinal inflammation decreases the frequency of CD5+ B cells and leads to a sustained CD5- B cell-dominant condition, which may be involved in the pathogenesis of refractory inflammatory bowel diseases (IBD).